EGEmma Goeman

Emma Goeman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Emma Goeman has a total of 19 co-authors. Here are the top co-authors by number of shared publications:

  • Antoine Gessain

    Institut Pasteur, Unité EPVO, Département de Virologie , F-75015 Paris , France ; CNRS, UMR 3569 , F-75015 Paris , France

    3 shared publications
  • Lloyd Einsiedel

    Northern Territory Rural Clinical School/Flinders University , Northern Territory of Australia , Australia ; SA Pathology, Adelaide , South Australia , Australia

    3 shared publications
  • Olivier Cassar

    Institut Pasteur, Unité EPVO, Département de Virologie , F-75015 Paris , France ; CNRS, UMR 3569 , F-75015 Paris , France

    3 shared publications
  • Tim Spelman

    Northern Territory Rural Clinical School/Flinders University , Northern Territory of Australia , Australia

    3 shared publications
  • Allan R. Glanville

    Heart and Lung Transplant Unit, St. Vincent's Hospital, Sydney, New South Wales, Australia

    1 shared publication
  • Aruna Shivam

    Heart and Lung Transplant Unit, St. Vincent's Hospital, Sydney, New South Wales, Australia

    1 shared publication

Latest Publications

  • Open Access

    Higher Human T-Lymphotropic Virus Type 1 Subtype C Proviral Loads Are Associated With Bronchiectasis in Indigenous Australians: Results of a Case-Control Study

    by Lloyd Einsiedel, Olivier Cassar, Emma Goeman, Tim Spelman, Virginia Au, Saba Hatami, Sheela Joseph, Antoine Gessain

    Background. We previously suggested that infection with the human T-lymphotropic virus type 1 (HTLV-1) subtype C is associated with bronchiectasis among Indigenous Australians. Bronchiectasis might therefore result from an HTLV-1-mediated inflammatory process that is typically associated with a high HTLV-1 proviral load (PVL). Human T-lymphotropic virus type 1 PVL have not been reported for Indigenous Australians. Methods. Thirty-six Indigenous adults admitted with bronchiectasis from June 1, 2008, to December 31, 2009 were prospectively recruited and matched by age, sex, and ethno-geographic origin to 36 controls. Case notes and chest high-resolution computed tomographs were reviewed, and pulmonary injury scores were calculated. A PVL assay for the HTLV-1c subtype that infects Indigenous Australians was developed and applied to this study. Clinical, radiological, and virological parameters were compared between groups and according to HTLV-1 serostatus. Results. Human T-lymphotropic virus type 1 infection was the main predictor of bronchiectasis in a multivariable model (adjusted risk ratio [aRR], 1.84; 95% confidence interval [CI], 1.19–2.84; P = .006). Moreover, the median HTLV-1c PVL (interquartile range) for cases was >100-fold that of controls (cases, 0.319 [0.007, 0.749]; controls, 0.003 [0.000, 0.051] per 100 peripheral blood lymphocytes; P = .007), and HTLV-1c PVL were closely correlated with radiologically determined pulmonary injury scores (Spearman's rho = 0.7457; P = .0000). Other predictors of bronchiectasis were positive Strongyloides serology (aRR, 1.69; 95% CI, 1.13–2.53) and childhood skin infections (aRR, 1.62; 95% CI, 1.07–2.44). Bronchiectasis was the major predictor of death (aRR, 2.71; 95% CI, 1.36–5.39; P = .004). Conclusions. These data strongly support an etiological association between HTLV-1 infection and bronchiectasis in a socially disadvantaged population at risk of recurrent lower respiratory tract infections.


  • Open Access

    Clinical Associations of Human T-Lymphotropic Virus Type 1 Infection in an Indigenous Australian Population

    by Lloyd Einsiedel, Tim Spelman, Emma Goeman, Olivier Cassar, Mick Arundell, Antoine Gessain

    In resource-poor areas, infectious diseases may be important causes of morbidity among individuals infected with the Human T-Lymphotropic Virus type 1 (HTLV-1). We report the clinical associations of HTLV-1 infection among socially disadvantaged Indigenous adults in central Australia. HTLV-1 serological results for Indigenous adults admitted 1st January 2000 to 31st December 2010 were obtained from the Alice Springs Hospital pathology database. Infections, comorbid conditions and HTLV-1 related diseases were identified using ICD-10 AM discharge morbidity codes. Relevant pathology and imaging results were reviewed. Disease associations, admission rates and risk factors for death were compared according to HTLV-1 serostatus. HTLV-1 western blots were positive for 531 (33.3%) of 1595 Indigenous adults tested. Clinical associations of HTLV-1 infection included bronchiectasis (adjusted Risk Ratio, 1.35; 95% CI, 1.14–1.60), blood stream infections (BSI) with enteric organisms (aRR, 1.36; 95% CI, 1.05–1.77) and admission with strongyloidiasis (aRR 1.38; 95% CI, 1.16–1.64). After adjusting for covariates, HTLV-1 infection remained associated with increased numbers of BSI episodes (adjusted negative binomial regression, coefficient, 0.21; 95% CI, 0.02–0.41) and increased admission numbers with strongyloidiasis (coefficient, 0.563; 95% CI, 0.17–0.95) and respiratory conditions including asthma (coefficient, 0.99; 95% CI, 0.27–1.7), lower respiratory tract infections (coefficient, 0.19; 95% CI, 0.04–0.34) and bronchiectasis (coefficient, 0.60; 95% CI, 0.02–1.18). Two patients were admitted with adult T-cell Leukemia/Lymphoma, four with probable HTLV-1 associated myelopathy and another with infective dermatitis. Independent predictors of mortality included BSI with enteric organisms (aRR 1.78; 95% CI, 1.15–2.74) and bronchiectasis (aRR 2.07; 95% CI, 1.45–2.98). HTLV-1 infection contributes to morbidity among socially disadvantaged Indigenous adults in central Australia. This is largely due to an increased risk of other infections and respiratory disease. The spectrum of HTLV-1 related diseases may vary according to the social circumstances of the affected population. The Human T-Lymphotropic Virus type 1 (HTLV-1) infects at least 5–10 million people worldwide. In developed countries, the most frequently reported HTLV-1 associated diseases include a fatal hematological malignancy, Adult T-cell Leukemia/Lymphoma (ATLL), and the neurological disorder, HTLV-1 associated myelopathy (HAM), which arise in <10% of HTLV-1 carriers during their lifetime. However, most HTLV-1 carriers live in resource-poor areas where infectious diseases, such as strongyloidiasis, could be more important causes of morbidity. Demonstrating such an effect is difficult due to the resource constraints experienced by developing countries in which populations with a substantial burden of infectious diseases reside in areas that are highly endemic for HTLV-1. This is not the case in HTLV-1 endemic central Australia where Indigenous Australians have, for example, among the highest reported blood stream infection rates worldwide in a setting in which sophisticated medical facilities are readily available. We report that bronchiectasis, blood stream infections and admissions with lower respiratory tract infections and strongyloidiasis are associated with HTLV-1 infection. These conditions were far more common than HTLV-1 associated malignancies or neurological conditions in this socially disadvantaged Indigenous population. The spectrum of HTLV-1 related diseases therefore varies according to the social circumstances of the affected population.


  • Hip to the heart

    by Gabrielle M Haeusler, Emma Goeman, Michael Cheung, Mick Creati, Nigel Curtis


  • Discussing withdrawing and withholding of life‐sustaining medical treatment in a tertiary paediatric hospital: A survey of clinician attitudes and practices

    by Tom Forbes, Emma Goeman, Zornitza Stark, Jenny Hynson, Mike Forrester

    To better understand current attitudes and practices relating to discussions concerning the withholding and withdrawing of life-sustaining medical treatment (WWLSMT) among medical staff in the paediatric setting. An anonymous online survey of paediatricians (senior medical staff - SMS) and paediatric trainees (junior medical staff - JMS) likely to be involved in the care of children with life limiting illness. A total of 162 responses were obtained (response rate 42%). SMS indicated feeling more comfortable with their abilities to discuss WWLSMT than JMS. Barriers to discussing WWLSMT were numerous and included clinician concerns about family readiness for the discussion, prognostic uncertainty, family disagreement with the treating team regarding the child's prognosis/diagnosis and concerns about how to manage family requests for treatments that are not perceived to be in the child's best interests. Fifty-eight per cent of JMS and 35.8% of SMS reported receiving no specific communication training regarding WWLSMT. Most learned through experience and by observing more senior colleagues. There was a high level of support for additional training in this area and for the provision of resources such as discussion guidelines and a structured form for documenting the outcomes WWLSMT discussions. The majority of JMS feel less comfortable with their abilities to facilitate these discussions than their senior colleagues. The results of this study suggest that although confidence correlates with experience, junior and senior clinicians are eager to improve their skills through ongoing professional development and the provision of resources. The education needs of JMS and SMS appear to be different.